A costing study of bortezomib shows equivalence of its real-world costs to conventional treatment

Nav

General Info

Geography

Australia (AUS)

Time period covered

01/2002 - 12/2012

Data type

Scientific literature

Keywords

Chemotherapy, Health care costs, Multiple myeloma

Citation

Authors

Thompson JF, Teh Z, Chen Y, Gardiner J, Bednarz JM, Thompson GN, Lee C, Horvath N, Bardy P, Yeung D

Journal

Br J Haematol

Volume

189

Issue

Pages

e76-e79

Publication year

2020

Suggested citation

Thompson JF, Teh Z, Chen Y, Gardiner J, Bednarz JM, Thompson GN, Lee C, Horvath N, Bardy P, Yeung D. A costing study of bortezomib shows equivalence of its real-world costs to conventional treatment. Br J Haematol. 2020; 189(3): e76-e79.

DOI

10.1111/bjh.16484

PMID

32004380

GHDx Entry last modified on: Mar 19, 2021

Header sites

Search form

Main menu

A costing study of bortezomib shows equivalence of its real-world costs to conventional treatment

Nav